Download PDF
Thromb Haemost 2023; 123(06): 627-640
DOI: 10.1055/a-2011-8426
Atherosclerosis and Ischaemic Disease

Post-PCI Risk Assessment by Inflammation Activity According to Disease Acuity and Time from Procedure

Haegeun Song
1   Division of Cardiology, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, South Korea
2   Department of Internal Medicine, Chung-Ang University College of Medicine, Gwangmyeong, South Korea
,
Jong-Hwa Ahn
3   Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, South Korea
,
Min Gyu Kang
4   Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea
5   Division of Cardiology, Gyeongsang National University Hospital, Jinju, South Korea
,
Kye-Hwan Kim
4   Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea
5   Division of Cardiology, Gyeongsang National University Hospital, Jinju, South Korea
,
Jae Seok Bae
3   Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, South Korea
,
Sang Young Cho
3   Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, South Korea
,
Jin-Sin Koh
4   Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea
5   Division of Cardiology, Gyeongsang National University Hospital, Jinju, South Korea
,
Yongwhi Park
3   Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, South Korea
,
Seok-Jae Hwang
4   Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea
5   Division of Cardiology, Gyeongsang National University Hospital, Jinju, South Korea
,
Eun Jeong Cho
1   Division of Cardiology, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, South Korea
2   Department of Internal Medicine, Chung-Ang University College of Medicine, Gwangmyeong, South Korea
,
Kyeongmin Byeon
1   Division of Cardiology, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, South Korea
2   Department of Internal Medicine, Chung-Ang University College of Medicine, Gwangmyeong, South Korea
,
Sang-Wook Kim
1   Division of Cardiology, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, South Korea
2   Department of Internal Medicine, Chung-Ang University College of Medicine, Gwangmyeong, South Korea
,
Udaya S. Tantry
6   Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, Maryland, United States
,
Paul A. Gurbel 
6   Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, Maryland, United States
,
Jin-Yong Hwang
4   Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea
5   Division of Cardiology, Gyeongsang National University Hospital, Jinju, South Korea
,
Young-Hoon Jeong 
7   CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, South Korea
8   Department of Internal Medicine, Chung-Ang University School of Medicine, Gwangmyeong, South Korea
› Author Affiliations Funding This study was supported by the Science Research Program through the CAU Thrombosis and Biomarker Center of Korea funded by the Chung-Ang University Gwangmyeong Hospital. The content is solely the responsibility of the authors and does not necessarily represent the official views of any funding agencies.
› Further Information
    Permissions and Reprints


Abstract

Background High-sensitivity C-reactive protein (hs-CRP) has been proposed as an indicator of inflammation and cardiovascular risk. However, little is known of the comparative temporal profile of hs-CRP and its relation to outcomes according to the disease acuity.

Methods We enrolled 4,263 East Asian patients who underwent percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) and stable disease. hs-CRP was measured at baseline and 1 month post-PCI. Major adverse cardiovascular events (MACE: the composite occurrence of death, myocardial infarction, or stroke) and major bleeding were followed up to 4 years.

Result The AMI group (n = 2,376; 55.7%) had higher hs-CRPbaseline than the non-AMI group (n = 1,887; 44.3%) (median: 1.5 vs. 1.0 mg/L; p < 0.001), which remained higher at 1 month post-PCI (median: 1.0 vs. 0.9 mg/L; p = 0.001). During 1 month, a high inflammatory-risk phenotype (upper tertile: hs-CRPbaseline ≥ 2.4 mg/L) was associated with a greater MACE in the AMI group (adjusted hazard ratio [HRadj]: 7.66; 95% confidence interval [CI]: 2.29–25.59; p < 0.001), but not in the non-AMI group (HRadj: 0.74; 95% CI: 0.12–4.40; p = 0.736). Between 1 month and 4 years, a high inflammatory-risk phenotype (upper tertile: hs-CRP1 month ≥ 1.6 mg/L) was associated with greater MACE compared to the other phenotype in both the AMI (HRadj: 2.40; 95% CI: 1.73–3.45; p < 0.001) and non-AMI groups (HRadj: 2.67; 95% CI: 1.80–3.94; p < 0.001).

Conclusion AMI patients have greater inflammation during the early and late phases than non-AMI patients. Risk phenotype of hs-CRPbaseline correlates with 1-month outcomes only in AMI patients. However, the prognostic implications of this risk phenotype appears similar during the late phase, irrespective of the disease acuity.

Keywords

coronary artery disease - acute myocardial infarction - C-reactive protein

REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT04650529.


Supplementary Material



Publication History

Received: 21 August 2022

Accepted: 10 January 2023

Accepted Manuscript online:
12 January 2023

Article published online:
24 February 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Libby P, Loscalzo J, Ridker PM. et al. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol 2018; 72 (17) 2071-2081
    CrossrefPubMedGoogle Scholar
  • 2 Ridker PM, Everett BM, Thuren T. et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377 (12) 1119-1131
    CrossrefPubMedGoogle Scholar
  • 3 Tardif J-C, Kouz S, Waters DD. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019; 381 (26) 2497-2505
    CrossrefPubMedGoogle Scholar
  • 4 Lawler PR, Bhatt DL, Godoy LC. et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J 2021; 42 (01) 113-131
    CrossrefPubMedGoogle Scholar
  • 5 Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J 2016; 37 (22) 1720-1722
    CrossrefPubMedGoogle Scholar
  • 6 Kalkman DN, Aquino M, Claessen BE. et al. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J 2018; 39 (46) 4101-4108
    CrossrefPubMedGoogle Scholar
  • 7 Ridker PM. A test in context: high-sensitivity C-reactive protein. J Am Coll Cardiol 2016; 67 (06) 712-723
    CrossrefPubMedGoogle Scholar
  • 8 James SK, Oldgren J, Lindbäck J, Johnston N, Siegbahn A, Wallentin L. An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. Am Heart J 2005; 149 (04) 619-626
    CrossrefPubMedGoogle Scholar
  • 9 Kang DO, Park Y, Seo JH. et al; KAMIR-NIH Registry Investigators. Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction. J Cardiol 2019; 74 (01) 74-83
    CrossrefPubMedGoogle Scholar
  • 10 Kim HK, Tantry US, Park H-W. et al. Ethnic difference of thrombogenicity in patients with cardiovascular disease: a pandora box to explain prognostic differences. Korean Circ J 2021; 51 (03) 202-221
    CrossrefPubMedGoogle Scholar
  • 11 Ahn JH, Tantry US, Kang MG. et al. Residual inflammatory risk and its association with events in east apan patients after coronary intervention. JACC Asia 2022; 2 (03) 323-337
    CrossrefPubMedGoogle Scholar
  • 12 Thygesen K, Alpert JS, Jaffe AS. et al; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol 2018; 72 (18) 2231-2264
    CrossrefPubMedGoogle Scholar
  • 13 Mehran R, Rao SV, Bhatt DL. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
    CrossrefPubMedGoogle Scholar
  • 14 Sanderson NC, Parker WAE, Storey RF. Ticagrelor: clinical development and future potential. Rev Cardiovasc Med 2021; 22 (02) 373-394
    CrossrefPubMedGoogle Scholar
  • 15 He LP, Tang XY, Ling WH, Chen WQ, Chen YM. Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies. Heart 2010; 96 (05) 339-346
    CrossrefPubMedGoogle Scholar
  • 16 James SK, Armstrong P, Barnathan E. et al; GUSTO-IV-ACS Investigators. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003; 41 (06) 916-924
    CrossrefPubMedGoogle Scholar
  • 17 Oemrawsingh RM, Cheng JM, Akkerhuis KM. et al. High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention. EuroIntervention 2016; 12 (03) 345-351
    CrossrefPubMedGoogle Scholar
  • 18 Schiele F, Meneveau N, Seronde MF. et al; Reseau de Cardiologie de Franche Comte. C-reactive protein improves risk prediction in patients with acute coronary syndromes. Eur Heart J 2010; 31 (03) 290-297
    CrossrefPubMedGoogle Scholar
  • 19 Kushner I, Broder ML, Karp D. Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. J Clin Invest 1978; 61 (02) 235-242
    PubMedGoogle Scholar
  • 20 Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 2004; 25 (05) 401-408
    CrossrefPubMedGoogle Scholar
  • 21 Sabatine MS, Morrow DA, Jablonski KA. et al; PEACE Investigators. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115 (12) 1528-1536
    CrossrefPubMedGoogle Scholar
  • 22 Takahashi N, Dohi T, Endo H. et al. Residual inflammation indicated by high-sensitivity C-reactive protein predicts worse long-term clinical outcomes in apanese patients after percutaneous coronary intervention. J Clin Med 2020; 9 (04) 1033
    CrossrefPubMedGoogle Scholar
  • 23 Bohula EA, Giugliano RP, Leiter LA. et al. Inflammatory and cholesterol risk in the FOURIER trial. Circulation 2018; 138 (02) 131-140
    CrossrefPubMedGoogle Scholar
  • 24 Held C, White HD, Stewart RAH. et al; STABILITY Investigators. Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial. J Am Heart Assoc 2017; 6 (10) e005077
    CrossrefPubMedGoogle Scholar
  • 25 Ridker PM, Rifai N, Pfeffer MA. et al; Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98 (09) 839-844
    CrossrefPubMedGoogle Scholar
  • 26 Ridker PM, Cannon CP, Morrow D. et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352 (01) 20-28
    CrossrefPubMedGoogle Scholar
  • 27 Bohula EA, Giugliano RP, Cannon CP. et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 2015; 132 (13) 1224-1233
    CrossrefPubMedGoogle Scholar
  • 28 Klingenberg R, Aghlmandi S, Gencer B. et al. Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events. Atherosclerosis 2021; 320: 31-37
    CrossrefPubMedGoogle Scholar
  • 29 Bouabdallaoui N, Tardif JC, Waters DD. et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J 2020; 41 (42) 4092-4099
    CrossrefPubMedGoogle Scholar
  • 30 Nidorf SM, Fiolet ATL, Mosterd A. et al; LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. N Engl J Med 2020; 383 (19) 1838-1847
    CrossrefPubMedGoogle Scholar
  • 31 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian Paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Kang J, Park KW, Palmerini T. et al. Racial differences in ischaemia/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost 2019; 119 (01) 149-162
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Golomb M, Redfors B, Crowley A. et al. Prognostic impact of race in patients undergoing PCI: analysis from 10 randomized coronary stent trials. JACC Cardiovasc Interv 2020; 13 (13) 1586-1595
    CrossrefPubMedGoogle Scholar